ArticleFrontiers in pharmacology2026
Cardiovascular toxicity of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in HR+/HER2- breast cancer: a real-world study based on the FAERS database.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study was designed to examine the relationship between CDK4/6 inhibitor therapy and cardiovascular adverse events (CVAEs). Method: A disproportionality analysis was performed on reports from the FDA Adverse Event Reporting System (FAERS) database covering the period from 2015 to the first quarter of 2025. The reporting odds ratio (ROR) and information components (IC) were derived from this analysis. CVAEs were categorized into ten specific groups based on the standardized MedDRA queries (SMQs). Multifactorial logistic regression analysis was conducted to identify factors associated with CVAEs following treatment with CDK4/6 inhibitors. Results: Analysis of 4,002 CVAEs associated with CDK4/6 inhibitors indicated a stronger reporting association of cardiotoxicity for ribociclib (OR = 1.55, p < 0.001), especially arrhythmia. Ribociclib + fulvestrant showed a strong arrhythmia signal (ROR = 2.86; n = 188), while ribociclib + letrozole had the strongest QT prolongation signal (ROR = 6.51; n = 291) and an increased reporting signal for shock (ROR = 4.33). Abemaciclib + fulvestrant exhibited stronger thrombotic signals (ROR = 2.50) than with letrozole (ROR = 1.24). Patients over 65 showed stronger CVAE signals (OR = 1.29, p < 0.001), further elevated by letrozole/fulvestrant combinations (OR = 1.83/1.32, p < 0.001). Most CVAEs occurred early (0-60 days), with peak incidence for ribociclib + letrozole at 0-30 days and late arrhythmia resurgence for ribociclib + fulvestrant (210-240 days). Shock-related mortality was the most fatal outcome; thrombotic events prolonged hospitalization. Conclusion: CDK4/6 inhibitor combinations show notable cardiovascular reporting signals, with more frequent CVAE reports in letrozole-containing regimens. These signals suggest enhanced vigilance for thrombosis, arrhythmias, QT prolongation, and shock may be warranted. Cohort and long-term trials are needed to validate these safety findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.